

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	Colesevelam hydrochloride
Brand Name	Lodalis™
Dosage Form(s)	625 mg
Manufacturer	Valeant Canada
Submission Review	New Submission
Use Reviewed	Lodalis™ is indicated for the reduction of cholesterol blood level in patients with hypercholesterolemia
Common Drug Review (CDR)	CDR recommended Do not list at the resubmitted price. http://www.cadth.ca/media/cdr/complete/cdr_complete_Lodalis_Decembe_21_12.pdf
Drug Benefit Council (DBC)	DBC met on March 11, 2013. The DBC considered the following: the final review completed by the Common Drug Review (CDR) on December 19, 2012, which included clinical and pharmacoeconomic evidence review material and the recommendation from the Canadian Drug Expert Committee (CDEC); Clinical Practice Reviews from two Specialists, Manufacturer comments, responses to Patient Input Questionnaires from one patient and one patient group and a Budget Impact Analysis.
Drug Coverage Decision	Non-Benefit
Date	June 13, 2013
Reason(s)	<p>Drug coverage decision is consistent with the DBC recommendation.</p> <ul style="list-style-type: none"> • The drug demonstrated a reduction in levels of LDL-C (bad cholesterol) compared to placebo. • The drug was not directly compared to two other similarly acting drugs, cholestyramine and colestipol, which are covered by PharmaCare. Thus, there is insufficient evidence that the drug is better than these alternatives. • Based on economic considerations and the submitted product price, the drug was not cost effective.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) gives advice to the Ministry. The Council looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C. and the drugs cost
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the Council
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, please visit
<http://www.health.gov.bc.ca/pharmacare/outgoing/drugrevproc2.pdf>.

To find out more about the Pharmaceutical Services Division and the PharmaCare program, visit
www.health.gov.bc.ca/pharmacare.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.